Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46


Non-coding RNAs open a new chapter in liver cancer treatment.

Gougelet A, Desbois-Mouthon C.

Clin Res Hepatol Gastroenterol. 2019 Aug 7. pii: S2210-7401(19)30170-6. doi: 10.1016/j.clinre.2019.07.005. [Epub ahead of print]


Insulin receptor isoform A favors tumor progression in human hepatocellular carcinoma by increasing stem/progenitor cell features.

Benabou E, Salamé Z, Wendum D, Lequoy M, Tahraoui S, Merabtene F, Chrétien Y, Scatton O, Rosmorduc O, Fouassier L, Fartoux L, Praz F, Desbois-Mouthon C.

Cancer Lett. 2019 May 28;450:155-168. doi: 10.1016/j.canlet.2019.02.037. Epub 2019 Mar 6.


Potentials of CRISPR in liver research and therapy.

Loesch R, Desbois-Mouthon C, Colnot S.

Clin Res Hepatol Gastroenterol. 2019 Feb;43(1):5-11. doi: 10.1016/j.clinre.2018.05.001. Epub 2018 Jun 5.


The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma.

Vaquero J, Lobe C, Tahraoui S, Clapéron A, Mergey M, Merabtene F, Wendum D, Coulouarn C, Housset C, Desbois-Mouthon C, Praz F, Fouassier L.

Clin Cancer Res. 2018 Sep 1;24(17):4282-4296. doi: 10.1158/1078-0432.CCR-17-3725. Epub 2018 May 1.


The beta secretase BACE1 regulates the expression of insulin receptor in the liver.

Meakin PJ, Mezzapesa A, Benabou E, Haas ME, Bonardo B, Grino M, Brunel JM, Desbois-Mouthon C, Biddinger SB, Govers R, Ashford MLJ, Peiretti F.

Nat Commun. 2018 Apr 3;9(1):1306. doi: 10.1038/s41467-018-03755-2.


Low Levels of Microsatellite Instability at Simple Repeated Sequences Commonly Occur in Human Hepatocellular Carcinoma.

Goumard C, Desbois-Mouthon C, Wendum D, Calmel C, Merabtene F, Scatton O, Praz F.

Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):329-339.


Growth factor receptor binding protein 14 inhibition triggers insulin-induced mouse hepatocyte proliferation and is associated with hepatocellular carcinoma.

Morzyglod L, Caüzac M, Popineau L, Denechaud PD, Fajas L, Ragazzon B, Fauveau V, Planchais J, Vasseur-Cognet M, Fartoux L, Scatton O, Rosmorduc O, Guilmeau S, Postic C, Desdouets C, Desbois-Mouthon C, Burnol AF.

Hepatology. 2017 Apr;65(4):1352-1368. doi: 10.1002/hep.28972. Epub 2017 Feb 21.


Erratum to: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin.

Buta C, Benabou E, Lequoy M, Régnault H, Wendum D, Merabtene F, Chettouh H, Aoudjehane L, Conti F, Chrétien Y, Scatton O, Rosmorduc O, Praz F, Fartoux L, Desbois-Mouthon C.

J Exp Clin Cancer Res. 2016 Sep 28;35(1):154. No abstract available.


Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin.

Buta C, Benabou E, Lequoy M, Régnault H, Wendum D, Meratbene F, Chettouh H, Aoudjehane L, Conti F, Chrétien Y, Scatton O, Rosmorduc O, Praz F, Fartoux L, Desbois-Mouthon C.

J Exp Clin Cancer Res. 2016 Aug 11;35(1):126. doi: 10.1186/s13046-016-0402-3. Erratum in: J Exp Clin Cancer Res. 2016;35(1):154.


Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis.

Lequoy M, Desbois-Mouthon C, Wendum D, Gupta V, Blachon JL, Scatton O, Dumont S, Bonnemaire M, Schmidlin F, Rosmorduc O, Fartoux L.

Histopathology. 2017 Feb;70(3):492-498. doi: 10.1111/his.13034. Epub 2016 Nov 10.


Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.

Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, Peix J, Cabellos L, Alsinet C, Torrecilla S, Martinez-Quetglas I, Lozano JJ, Desbois-Mouthon C, Solé M, Domingo-Domenech J, Villanueva A, Llovet JM.

Gut. 2017 Mar;66(3):530-540. doi: 10.1136/gutjnl-2015-309501. Epub 2015 Dec 11.


Mitogen-activated protein kinase-activated protein kinase 2 mediates resistance to hydrogen peroxide-induced oxidative stress in human hepatobiliary cancer cells.

Nguyen Ho-Bouldoires TH, Clapéron A, Mergey M, Wendum D, Desbois-Mouthon C, Tahraoui S, Fartoux L, Chettouh H, Merabtene F, Scatton O, Gaestel M, Praz F, Housset C, Fouassier L.

Free Radic Biol Med. 2015 Dec;89:34-46. doi: 10.1016/j.freeradbiomed.2015.07.011. Epub 2015 Jul 11.


Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma.

Chettouh H, Lequoy M, Fartoux L, Vigouroux C, Desbois-Mouthon C.

Liver Int. 2015 Oct;35(10):2203-17. doi: 10.1111/liv.12903. Epub 2015 Jul 23. Review.


Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor.

Clapéron A, Mergey M, Aoudjehane L, Ho-Bouldoires TH, Wendum D, Prignon A, Merabtene F, Firrincieli D, Desbois-Mouthon C, Scatton O, Conti F, Housset C, Fouassier L.

Hepatology. 2013 Dec;58(6):2001-11. doi: 10.1002/hep.26585. Epub 2013 Oct 25. Erratum in: Hepatology. 2014 Aug;60(2):770.


Involvement of small ArfGAP1 (SMAP1), a novel Arf6-specific GTPase-activating protein, in microsatellite instability oncogenesis.

Sangar F, Schreurs AS, Umaña-Diaz C, Clapéron A, Desbois-Mouthon C, Calmel C, Mauger O, Zaanan A, Miquel C, Fléjou JF, Praz F.

Oncogene. 2014 May 22;33(21):2758-67. doi: 10.1038/onc.2013.211. Epub 2013 Jun 10.


Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors.

Chettouh H, Fartoux L, Aoudjehane L, Wendum D, Clapéron A, Chrétien Y, Rey C, Scatton O, Soubrane O, Conti F, Praz F, Housset C, Rosmorduc O, Desbois-Mouthon C.

Cancer Res. 2013 Jul 1;73(13):3974-86. doi: 10.1158/0008-5472.CAN-12-3824. Epub 2013 Apr 30.


Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.

Blivet-Van Eggelpoël MJ, Chettouh H, Fartoux L, Aoudjehane L, Barbu V, Rey C, Priam S, Housset C, Rosmorduc O, Desbois-Mouthon C.

J Hepatol. 2012 Jul;57(1):108-15. doi: 10.1016/j.jhep.2012.02.019. Epub 2012 Mar 10.


Loss of EBP50 stimulates EGFR activity to induce EMT phenotypic features in biliary cancer cells.

Clapéron A, Guedj N, Mergey M, Vignjevic D, Desbois-Mouthon C, Boissan M, Saubaméa B, Paradis V, Housset C, Fouassier L.

Oncogene. 2012 Mar 15;31(11):1376-88. doi: 10.1038/onc.2011.334. Epub 2011 Aug 8.


Targeting STAT3 in hepatocellular carcinoma: sorafenib again….

Rosmorduc O, Desbois-Mouthon C.

J Hepatol. 2011 Nov;55(5):957-9. doi: 10.1016/j.jhep.2011.06.005. Epub 2011 Jun 28. No abstract available.


Implication of metastasis suppressor NM23-H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells.

Boissan M, De Wever O, Lizarraga F, Wendum D, Poincloux R, Chignard N, Desbois-Mouthon C, Dufour S, Nawrocki-Raby B, Birembaut P, Bracke M, Chavrier P, Gespach C, Lacombe ML.

Cancer Res. 2010 Oct 1;70(19):7710-22. doi: 10.1158/0008-5472.CAN-10-1887. Epub 2010 Sep 14.


The HER3/ErbB3 receptor: a promising target in cancer drug therapy.

Desbois-Mouthon C.

Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):255-9. doi: 10.1016/j.gcb.2010.03.002. Epub 2010 Apr 24. No abstract available.


Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.

Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O.

Clin Cancer Res. 2009 Sep 1;15(17):5445-56. doi: 10.1158/1078-0432.CCR-08-2980. Epub 2009 Aug 25.


Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells.

Beurel E, Blivet-Van Eggelpoël MJ, Kornprobst M, Moritz S, Delelo R, Paye F, Housset C, Desbois-Mouthon C.

Biochem Pharmacol. 2009 Jan 1;77(1):54-65. doi: 10.1016/j.bcp.2008.09.026. Epub 2008 Oct 1.


[Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].

Fartoux L, Desbois-Mouthon C, Poupon R, Rosmorduc O.

Gastroenterol Clin Biol. 2006 Oct;30(10):1133-5. Review. French. No abstract available.


Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.

Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoël MJ, Barbu V, Fartoux L, Poupon R, Housset C, Rosmorduc O.

Int J Cancer. 2006 Dec 1;119(11):2557-66.


Hepatocyte proliferation during liver regeneration is impaired in mice with liver-specific IGF-1R knockout.

Desbois-Mouthon C, Wendum D, Cadoret A, Rey C, Leneuve P, Blaise A, Housset C, Tronche F, Le Bouc Y, Holzenberger M.

FASEB J. 2006 Apr;20(6):773-5. Epub 2006 Feb 16.


Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma.

Boissan M, Beurel E, Wendum D, Rey C, Lécluse Y, Housset C, Lacombe ML, Desbois-Mouthon C.

Am J Pathol. 2005 Sep;167(3):869-77.


GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis.

Beurel E, Kornprobst M, Blivet-Van Eggelpoël MJ, Cadoret A, Capeau J, Desbois-Mouthon C.

Int J Oncol. 2005 Jul;27(1):215-22.


Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis.

Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, Clergue F, Poupon R, Barbu V, Rosmorduc O.

Hepatology. 2005 Feb;41(2):307-14.


c-myc-induced hepatocarcinogenesis in the absence of IGF-I receptor.

Cadoret A, Desbois-Mouthon C, Wendum D, Leneuve P, Perret C, Tronche F, Housset C, Holzenberger M.

Int J Cancer. 2005 Apr 20;114(4):668-72.


GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression.

Beurel E, Kornprobst M, Blivet-Van Eggelpoël MJ, Ruiz-Ruiz C, Cadoret A, Capeau J, Desbois-Mouthon C.

Exp Cell Res. 2004 Nov 1;300(2):354-64.


Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells.

Desbois-Mouthon C, Blivet-Van Eggelpoël MJ, Beurel E, Boissan M, Delélo R, Cadoret A, Capeau J.

Hepatology. 2002 Dec;36(6):1528-36.


Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of toll-like receptor 2.

Imasato A, Desbois-Mouthon C, Han J, Kai H, Cato AC, Akira S, Li JD.

J Biol Chem. 2002 Dec 6;277(49):47444-50. Epub 2002 Sep 27.


[Major insulin resistance syndromes: clinical and physiopathological aspects].

Vigouroux C, Magré J, Desbois-Mouthon C, Lascols O, Cherqui G, Caron M, Capeau J.

J Soc Biol. 2001;195(3):249-57. Review. French.


Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation.

Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoël MJ, Bertrand F, Cherqui G, Perret C, Capeau J.

Oncogene. 2001 Jan 11;20(2):252-9.


Insulin-mediated cell proliferation and survival involve inhibition of c-Jun N-terminal kinases through a phosphatidylinositol 3-kinase- and mitogen-activated protein kinase phosphatase-1-dependent pathway.

Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoël MJ, Bertrand F, Caron M, Atfi A, Cherqui G, Capeau J.

Endocrinology. 2000 Mar;141(3):922-31.


Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and -2 and cause severe cell resistance to both insulin and insulin-like growth factor I.

Auclair M, Vigouroux C, Desbois-Mouthon C, Deibener J, Kaminski P, Lascols O, Cherqui G, Capeau J, Caron M.

J Clin Endocrinol Metab. 1999 Sep;84(9):3197-206.


Late-onset lipoatrophic diabetes. Phenotypic and genotypic familial studies and effect of treatment with metformin and lispro insulin analog.

Vantyghem MC, Vigouroux C, Magré J, Desbois-Mouthon C, Pattou F, Fontaine P, Lefebvre J, Capeau J.

Diabetes Care. 1999 Aug;22(8):1374-6. No abstract available.


Insulin differentially regulates SAPKs/JNKs and ERKs in CHO cells overexpressing human insulin receptors.

Desbois-Mouthon C, Blivet-Van Eggelpoel MJ, Auclair M, Cherqui G, Capeau J, Caron M.

Biochem Biophys Res Commun. 1998 Feb 24;243(3):765-70.


Dominant transmission of insulin resistance in a type A family resulting from a heterozygous nonsense mutation in the insulin receptor gene and associated with decreased mRNA level and insulin binding sites.

Magré J, Karayanni C, Hadjiathanasiou CG, Desbois-Mouthon C, Meier M, Vigouroux C, Stavrinadis C, Sinaniotis C, Caron M, Capeau J.

Diabetes. 1997 Nov;46(11):1901-3. No abstract available.


Molecular analysis of the insulin receptor gene for prenatal diagnosis of leprechaunism in two families.

Desbois-Mouthon C, Girodon E, Ghanem N, Caron M, Pennerath A, Conteville P, Magre J, Besmond C, Goossens M, Capeau J, Amselem S.

Prenat Diagn. 1997 Jul;17(7):657-63.


Major circadian variations of glucose homeostasis in a patient with Rabson-Mendenhall syndrome and primary insulin resistance due to a mutation (Cys284-->Tyr) in the insulin receptor alpha-subunit.

Desbois-Mouthon C, Magré J, Duprey J, Caron M, Blivet-Van Eggelpoel MJ, Daubas C, Gourmelen M, Chevallier B, Rizkalla S, Robert JJ, Capeau J.

Pediatr Res. 1997 Jul;42(1):72-7.


Severe resistance to insulin and insulin-like growth factor-I in cells from a patient with leprechaunism as a result of two mutations in the tyrosine kinase domain of the insulin receptor.

Desbois-Mouthon C, Danan C, Amselem S, Blivet-Van Eggelpoel MJ, Sert-Langeron C, Goossens M, Besmond C, Capeau J, Caron M.

Metabolism. 1996 Dec;45(12):1493-500.


Deletion of Asn281 in the alpha-subunit of the human insulin receptor causes constitutive activation of the receptor and insulin desensitization.

Desbois-Mouthon C, Sert-Langeron C, Magre J, Oreal E, Blivet MJ, Flori E, Besmond C, Capeau J, Caron M.

J Clin Endocrinol Metab. 1996 Feb;81(2):719-27.


Lipoatrophic diabetes: genetic exclusion of the insulin receptor gene.

Desbois-Mouthon C, Magré J, Amselem S, Reynet C, Blivet MJ, Goossens M, Capeau J, Besmond C.

J Clin Endocrinol Metab. 1995 Jan;80(1):314-9.


Supplemental Content

Loading ...
Support Center